GRAL
GRAIL, Inc. Common StockGRAL
GRAL
About: GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Employees: 1,000
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
91% more call options, than puts
Call options by funds: $21M | Put options by funds: $11M
29% more capital invested
Capital invested by funds: $476M [Q4 2024] → $613M (+$137M) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 86
5% less funds holding
Funds holding: 322 [Q4 2024] → 306 (-16) [Q1 2025]
8.46% less ownership
Funds ownership: 79.23% [Q4 2024] → 70.77% (-8.46%) [Q1 2025]
23% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 57
25% less funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 3 (-1) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
52%
downside
Avg. target
$32
24%
downside
High target
$43
4%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Canaccord Genuity Kyle Mikson | 4%upside $43 | Buy Maintained | 14 May 2025 |
Morgan Stanley Tejas Savant | 52%downside $20 | Equal-Weight Maintained | 18 Mar 2025 |
Financial journalist opinion
Based on 4 articles about GRAL published over the past 30 days
Neutral
Schaeffers Research
2 days ago
These 24 Stocks Are Ripe for a Short Squeeze
With the way negative stock market sentiment has piled up recently, short squeezes have generated some massive returns.
Positive
MarketBeat
6 days ago
3 Medical Technology Stocks Outperforming in 2025
As the broader market stages a sharp rebound from its April lows, several sectors, industries, and stocks have quietly emerged as leaders. Among them, the medical technology industry, known for its innovation and growth potential, has stood out.
Neutral
PRNewsWire
2 weeks ago
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif. , May 30, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 77,350 shares of GRAIL's common stock to 38 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.
Neutral
PRNewsWire
3 weeks ago
GRAIL to Present at Jefferies Global Healthcare Conference 2025
MENLO PARK, Calif. , May 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Jefferies Global Healthcare Conference 2025 in New York on Tuesday, June 4 at 11:40 a.m.
Negative
Benzinga
1 month ago
Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.
Neutral
Seeking Alpha
1 month ago
GRAIL, Inc. (GRAL) Q1 2025 Earnings Call Transcript
GRAIL, Inc. (NASDAQ:GRAL ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Bob Ragusa - CEO Aaron Freidin - CFO Joshua Ofman - President Harpal Kumar - President, International Business and BioPharma Andy Partridge - Chief Commercial Officer Conference Call Participants Subbu Nabi - Guggenheim Partners Tejas Savant - Morgan Stanley Doug Schenkel - Wolfe Research Kyle Mikson - Canaccord Operator Good day, ladies and gentlemen. And welcome to the GRAIL First Quarter 2025 Earnings Call.
Neutral
PRNewsWire
1 month ago
GRAIL Reports First Quarter 2025 Financial Results
Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif. , May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025.
Neutral
PRNewsWire
1 month ago
GRAIL and athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test
MENLO PARK, Calif. , May 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with athenahealth, a leading provider of network-enabled software and services for healthcare practices and systems nationwide.
Neutral
PRNewsWire
1 month ago
GRAIL to Announce First Quarter 2025 Financial Results
MENLO PARK, Calif. , April 29, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2025 following the close of market on Tuesday, May 13, 2025.
Neutral
PRNewsWire
1 month ago
GRAIL to Present New Data on Galleri® and its Methylation Platform at American Association for Cancer Research (AACR) Annual Meeting
Real-World Data in 100,000 Patients Further Support the Galleri® Test's Ability to Simultaneously Screen for Multiple Cancers, as Well as its Accuracy of Cancer Signal of Origin Prediction to Support More Efficient Diagnostic Evaluations Data From GRAIL's ctDNA-based Targeted Methylation Assay Highlight Potential to Identify Robust Signals of Promoter Methylation MENLO PARK, Calif. , April 22, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present new data highlighting the latest real-world evidence with the Galleri® multi-cancer early detection (MCED) test and additional data from GRAIL's circulating tumor DNA (ctDNA)-based targeted methylation platform at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 25-30, 2025.
Charts implemented using Lightweight Charts™